SGN-CD19A

SGN-CD19A
Monoclonal antibody
Type ?
Source Humanized (from mouse)
Target CD19
Clinical data
ATC code none
Identifiers

SGN-CD19A is an antibody-drug conjugate (ADC) directed to CD19 designed for the treatment of CD19-positive acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.[1] It consists of an anti-CD19 mAb linked to monomethyl auristatin F (MMAF), a cytotoxic agent.[2]

Also known as Denintuzumab mafodotin[3] Denintuzumab refers to the anti-CD19 antibody, and mafodotin refers to MMAF and the chemical linkage.[4]

Clinical trials

The drug is currently in phase I clinical trials.[5] Preliminary phase I results for B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL) and B-lineage acute lymphocytic leukemia (B-ALL) are being presented at the ASH medical conference Dec 2015.[3]

Phase 2

A separate randomized phase 2 trial has started in 2015 to evaluate SGN-CD19A in combination with R-ICE chemotherapy for second-line DLBCL.[3]

A phase 2 clinical trial in front-line DLBCL is due to start in 2016.[3]

References


This article is issued from Wikipedia - version of the 12/8/2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.